Zogenix, Inc. (ZGNX)
(Delayed Data from NSDQ)
$38.02 USD
-0.18 (-0.47%)
Updated May 3, 2019 04:00 PM ET
After-Market: $38.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.02 USD
-0.18 (-0.47%)
Updated May 3, 2019 04:00 PM ET
After-Market: $38.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Zogenix (ZGNX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zogenix (ZGNX) delivered earnings and revenue surprises of -8.89% and 1.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Zogenix (ZGNX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: ZGNX's Acquisition News, REGN, BLUE's Updates & More
by Zacks Equity Research
Regulatory and other pipeline updates from Zogenix (ZGNX) and Regeneron (REGN) are among a few key highlights from the biotech sector during the past week.
Zogenix (ZGNX) Stock Surges on Acquisition Offer From UCB
by Zacks Equity Research
Belgium-based UCB is set to acquire Zogenix (ZGNX) for a total transaction value of $1.9 billion in cash. The transaction is likely to be completed by second-quarter 2022.
Zogenix (ZGNX) Stock Jumps 65.7%: Will It Continue to Soar?
by Zacks Equity Research
Zogenix (ZGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zogenix (ZGNX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zogenix (ZGNX) delivered earnings and revenue surprises of -8.33% and 0.49%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Zogenix (ZGNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zogenix (ZGNX) Moves 6.2% Higher: Will This Strength Last?
by Zacks Equity Research
Zogenix (ZGNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zogenix (ZGNX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zogenix (ZGNX) delivered earnings and revenue surprises of -12.90% and 10.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zogenix (ZGNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zogenix (ZGNX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zogenix (ZGNX) delivered earnings and revenue surprises of -2.04% and 9.65%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Zogenix (ZGNX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zogenix (ZGNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zogenix (ZGNX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zogenix (ZGNX) delivered earnings and revenue surprises of -0.99% and 50.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Zogenix (ZGNX)
by Zacks Equity Research
Zogenix (ZGNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zogenix (ZGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Zogenix (ZGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zogenix (ZGNX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Zogenix (ZGNX) delivered earnings and revenue surprises of 5.88% and -6.18%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Zogenix (ZGNX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zogenix (ZGNX) in Focus: Stock Moves 7.6% Higher
by Zacks Equity Research
Zogenix (ZGNX) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Biotech Stock Roundup: GILD Prices Remdesivir, VXRT Rises, ICPT Plunges & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline developments.
Zogenix Gets FDA Nod for Dravet Syndrome Seizure Treatment
by Zacks Equity Research
Zogenix (ZGNX) gets FDA nod for Fintepla oral solution, CIV for the treatment of seizures associated with Dravet Syndrome in patients 2 years of age or older.
Are Options Traders Betting on a Big Move in Zogenix (ZGNX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Zogenix (ZGNX) stock based on the movements in the options market lately.
Zogenix (ZGNX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zogenix (ZGNX) delivered earnings and revenue surprises of 35.19% and 24.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Zogenix (ZGNX) This Earnings Season?
by Zacks Equity Research
Zogenix (ZGNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
How Zogenix (ZGNX) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Zogenix (ZGNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.